Stay updated on Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Added Minnesota under the Locations section and removed the Minnesota Locations entry. Page revision updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T08:09:56.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision from v3.3.1 to v3.3.2 appears to be a minor update to page formatting or documentation; no changes to study content, eligibility criteria, endpoints, or locations were changed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T16:33:10.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Revision indicator updated from v3.2.0 to v3.3.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T11:24:06.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    A government funding/status notice has been removed from the study page; core trial information, eligibility criteria, and contact details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-17T06:13:56.000Z thumbnail image
  8. Check
    63 days ago
    Change Detected
    Summary
    No substantive changes detected to core study content. The information presented remains the same, including objectives, eligibility criteria, and outcomes.
    Difference
    0.3%
    Check dated 2025-11-03T00:48:17.000Z thumbnail image
  9. Check
    92 days ago
    Change Detected
    Summary
    Key updates: version bump to v3.2.0 and the addition of an operating-status notice; the previous v3.1.0 reference was removed.
    Difference
    3%
    Check dated 2025-10-05T07:30:37.000Z thumbnail image

Stay in the know with updates to Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page.